The roles of intrarenal angiotensin (A) and thromboxane (TX) in the vascular hypersensitivity to renal nerve stimulation (RNS) and paradoxical vasoconstriction to renal perfusion pressure (RPP) reduction in the autoregulatory range in 1 wk norepinephrine (NE)-induced acute renal failure (ARF) in rats were investigated. Renal blood flow (RBF) responses were determined before and during intrarenal infusion of an AII and TXA2 antagonist. Saralasin or SQ29548 alone partially corrected the slopes of RBF to RNS and RPP reduction in NE-ARF rats (P < 0.02). Saralasin + SQ29548 normalized the RBF response to RNS. While combined saralasin + SQ29548 eliminated the vasoconstriction to RPP reduction, similar to the effect of renal denervation, appropriate vasodilatation was not restored. Renal vein norepinephrine efflux during RNS was disproportionately increased in NE-ARF (P < 0.001) and was suppressed by saralasin + SQ29548 infusion (P < 0.005).
Introduction
Clinical and laboratory evidence indicates that basal renal blood flow (RBF)' returns to > 40% of normal in the maintenance phase ofischemic acute renal failure (ARF) (1) (2) (3) . However, experimental studies have shown that the stimulated reactivity of the renal vasculature to neurohormonal agents is abnormal in this setting. In both the renal artery clamp and norepinephrine models of ARF there is a loss of the normal RBF autoregulatory response to a reduction in renal perfusion pressure (RPP) (4) (5) (6) . In addition, in the latter model there is a paradoxical vasoconstriction to RPP reduction and hypersensitivity to renal nerve stimulation (RNS) (7) . The hypersensitivity to RNS coupled with the observation that renal denerva-tion corrects the paradoxical vasoconstriction to RPP reduction suggests that increased sensitivity to renal adrenergic nerve activity may be related to the aberrant response to reduction in RPP (7) .
The mechanism of hypersensitivity to RNS, and presumed exaggerated vascular response to spontaneous renal adrenergic nerve activity, in ischemic ARF is unknown. However, several studies have demonstrated that both angiotensin and thromboxane can augment the vasoconstrictor response to RNS (8) (9) (10) (11) (12) . Whereas the enhancing property of either angiotensin or thromboxane is not fully understood, it appears to be more than a simple additive pressor effect because it can be induced with subpressor doses and is not similarly observed with intravascular norepinephrine infusion (8) (9) (10) 12) .
The possibility that angiotensin and/or thromboxane may be responsible for the hypersensitivity to adrenergic nerve stimulation in ischemic ARF is supported by experimental studies that have demonstrated increases in both hormones after ischemic injury. Hayes et al. (13) and DiBona and Sawin (14) have shown that renal renin activity is elevated and Hatziantoniou and Papanikolaou (15) have shown increases in urinary thromboxane B2 (TXB2) excretion in ischemic ARF models.
In the present study it was proposed that the increased vascular sensitivity to renal adrenergic nerve activity, as manifest experimentally by a hypersensitivity to RNS, was due to the enhancing effect of increases in intrarenal angiotensin and/or thromboxane. To examine this hypothesis, we measured RBF responses to RNS and RPP reduction in ischemic ARF and control rats before and after infusion of competitive antagonists of angiotensin II (AII) and thromboxane A2 (TXA2) alone or in combination. The results were compared to those observed before and after renal denervation. To determine if the effects of AII and TX inhibition were mediated through a reduction in adrenergic neurotransmitter release, changes in renal vein norepinephrine were measured before and during RNS.
Methods
The disease model, NE-induced ARF, has been described previously (2) . Briefly, adult Sprague-Dawley rats weighing 250-300 g underwent right nephrectomy 10 d before disease induction. After pentobarbital anesthesia, the left renal pedicle was exposed and NE was delivered at 0.6 gg/kg -min-' for 90 min into the renal artery. The rats were returned to metabolic cages receiving water ad lib and a low-potassium diet (ICN Pharmaceuticals, Cleveland, OH) for 72 h and a standard rat chow diet (Wayne Feed, Longmont, CO) thereafter. Peak azotemia occurred between 24 and 48 h after NE infusion. Renal blood flow returned to 70% ofcontrol levels by 24 
Results
Kidney weights and plasma electrolytes. NE-ARF kidneys appeared edematous and larger than those in sham-ARF rats. Mean group wet and dry weights of NE-ARF or sham-ARF kidneys from each protocol were similar. The mean wet weights of all NE-ARF and sham-ARF kidneys were 2.66±0.24 and 1.42±0.21 g, respectively (P < 0.001). Dry weights of these same kidneys were only slightly different (0.63±0.14 g in NE-ARF and 0.42±0.12 g in sham-ARF, P < 0.05) confirming that the greater weight in the former was predominantly tissue water. The levels of blood pH, plasma sodium, potassium, calcium, and magnesium were not different between sham-ARF and NE-ARF rats.
Effect ofintrarenalAII inhibition. The respective CIN in the sham-ARF and NE-ARF kidneys were 1.25±0.05 and 0.38±0.23 ml/min, respectively. These values were different at P < 0.001. Saralasin had no effect on the responses to RNS or RPP reduction in the sham-ARF kidneys as illustrated in Figs. I and 2. Baseline RBF before and during saralasin infusion and slopes of RBF to RNS and RPP reduction are shown in Table I .
In the NE-ARF rats, baseline preinfusion RBF was not different from that in sham-ARF kidneys. RBF slopes to RNS and RPP reduction were both significantly greater than the corresponding preinfusion values in sham-ARF kidneys at P < 0.001 (Figs. 1 and 2 and Table II) . Baseline RBF during saralasin was similar to the preinfusion value. However, the slope of RBF to RNS was decreased significantly from the preinfusion slope at P < 0.001. The slope of RBF to RNS during saralasin was still greater than the corresponding pre-or postinfusion value in sham-ARF kidneys at P < 0.05. The slope of RBF to RPP reduction with saralasin was less than presaralasin (P < 0.02), but greater than the corresponding measurement in sham-ARF kidneys (P < 0.001).
Mean reductions in RVR with RPP reduction in sham-ARF rats were similar before and during saralasin. In NE-ARF rats preinfusion RVR increased by 10.08±1.12 mmHg/ ml * min-'. With saralasin infusion the increase in RVR was reduced to 4.64±0.88 mmHg/ml -min-' (P < 0.001). However, the RVR with saralasin in NE-ARF kidneys remained greater than in sham-ARF kidneys (P < 0.001).
Effect of intrarenal TXA2 inhibition. CIN in the NE-ARF rats was less than half that in sham-ARF rats (0.43±0.51 vs. 1.11±0.14 ml/min, P < 0.001). As with saralasin, SQ29548 had no detectable effect in sham-ARF kidneys as demonstrated in Figs. 3 and 4 . Slopes of RBF to RNS and to RPP reduction before and during SQ29548 infusion, respectively, were not different (Table I) .
In NE-ARF kidneys, preinfusion slopes of RBF to RNS and RPP reduction were similar to the corresponding preinfusion values in NE-ARF rats given saralasin. With the addition of SQ29548, baseline RBF was not different from preinfusion; however, the slopes of RBF to RNS and RPP reduction were reduced compared to the corresponding preinfusion values as shown in Table I Fig. 1 . significantly by SQ29548, they remained greater than the corresponding values in sham-ARF animals. Renovascular resistance changes before and during SQ29548 infusion in sham-ARF kidneys were not different. In NE-ARF kidneys, the increase in RVR was attenuated significantly during TXA2 antagonist infusion (P < 0.001). However, the RVR during infusion remained greater than in sham-ARF kidneys (P < 0.001).
Effect of simultaneous AII and TXA2 inhibition. The CIN levels in sham-ARF and NE-ARF kidneys were 1.02±0.30 and 0.34±0.20 ml/min, respectively, different at P < 0.001. The respective CIN levels in the sham-ARF and NE-ARF kidneys were not different from those measured in the saralasin or SQ29548-only infusion protocols. Baseline RBF and slopes of RBF to RNS and RPP reduction in the sham-ARF rats before and during saralasin + SQ29548 were similar as illustrated in Figs. 5 and 6 and specified in Table I .
In NE-ARF rats baseline RBF before and during saralasin + SQ29548 infusion were not different. While comparative slopes to RPP reduction between sham-ARF and NE-ARF after saralasin + SQ29548 remained different at P < 0.001, those to RNS were similar (Figs. 5 and 6 and Table I ). The decreases in RBF slopes to RNS and RPP reduction with combined saralasin + SQ29548 were both significantly greater than those with either saralasin or SQ29548 given alone (both P < 0.02).
Changes in RVR with RPP reduction were not different before and during saralasin + SQ29548 in sham-ARF kidneys. In NE-ARF kidneys the preinfusion RVR was +12.86±0.80 mmHg/ml * min-'; however, during infusion it was reduced to + 1.78±0.28 mmHg/ml min-' (P < 0.001). The increase in this latter value was significantly less than that with infusion of only saralasin or SQ29548 (both P < 0.01); however, it remained significantly different from the corresponding RVR in sham-ARF rats.
Effect of renal denervation. Renal blood flow responses to RPP reduction in NE-ARF with acute renal denervation are shown in Fig. 7 . After denervation, baseline RBF was not significantly greater than the predenervation value; however, the slope of RBF to RPP reduction and corresponding RVR were reduced substantially as indicated in Table I (P < 0.001).
The postdenervation slope of RBF to RPP reduction and RVR, while less than the same respective values in NE-ARF rats during either saralasin or SQ29548 alone, were similar to those during combined saralasin and SQ29548 infusion.
Renal vein norepinephrine. The concentrations of renal venous plasma norepinephrine concentrations and efflux rates are shown in Table I . Baseline norepinephrine efflux rates were elevated in NE-ARF compared to sham-ARF rats. The absolute increase in efflux rate during RNS was significantly greater ifn the NE-ARF group (P < 0.01). The prestimulation norepinephrine efflux rate did not change detectably during saralasin Frequency of Stimulation (Hz) Figure 3 . Renal blood flow response to renal nerve stimulation before and during intrarenal SQ29548 infusion in sham-ARF control and NE-ARF kidneys. The slope of RBF to RNS was reduced during SQ29548 in NE-ARF kidneys (P < 0.01). Respective symbols are the same as in Fig. 1 . Renal Perfusion Pressure (mm Hg) Figure 4 . Renal blood flow response to renal perfusion pressure reduction before and during intrarenal SQ29548 infusion in sham-ARF control and NE-ARF kidneys. The slope of RBF to RPP reduction was reduced during SQ29548 in NE-ARF kidneys (P < 0.02).
Respective symbols are the same as in Fig. 1 .
Adrenergic Nerve Sensitivity in Acute Renal Failure 1535 TT + SQ29548 infusion in the NE-ARF group. During RNS, there was no increase in norepinephrine efflux with saralasin + SQ29548 which was significantly different from the response before All and TXA2 inhibition (P < 0.001).
Renal venous norepinephrine efflux was also measured before and after renal denervation in NE-ARF kidneys. Efflux rate was 556±102 before and 305±58 pg/min after denervation. These values were different by paired analysis at P < 0.02.
Discussion
Adams et al. (4), Matthys and associates (5), and Conger (6) demonstrated that there was a loss of RBF autoregulation in experimental ischemic ARF. In subsequent experiments it was found that the pattern of RBF response to RPP reduction was not that of functionally unresponsive renal resistance vessels; but rather, there was a striking paradoxical increase in RVR as RPP was lowered in the autoregulatory range (7) . Moreover, denervation of the kidney, while not restoring normal RBF autoregulation, obliterated the vasoconstriction to decreases in RPP (7) . A potential role for accelerated renal adrenergic nerve activity in recurrent ischemic injury in the maintenance phase of NE-ARF was supported by experiments in which renal denervation was carried out before transient reduction in RPP. Unlike rats with intact renal nerves, those with renal denervation had neither recurrent increases in blood urea nitrogen or serum creatinine nor new ischemic lesions in the kidneys (22) . These data appeared to implicate enhanced response to adrenergic nerve impulses in the abnormal vascular sensitivity to RPP manipulation in established ischemic ARF.
The present study was carried out to investigate the mechanism of hypersensitivity to RNS. Two parallel observation suggested roles for angiotensin and thromboxane. First, reninangiotensin and thromboxane activity are known to be increased after ischemic injury to the kidney. Several investigators have measured increases in plasma and renal renin activity in clinical and experimental ARF (13, 14, (23) (24) (25) . Others have provided evidence that renal thromboxane activity is elevated after ischemia (15, 26). The second related observation is that All and TX are known to potentiate RNS-induced vasoconstriction (8-10, 12, 27, 28) . While angiotensin has been shown to enhance and thromboxane synthetase inhibition to decrease vasoconstriction to RNS, these agents have had little effect on the response to infused NE (8, 12 ), suggesting that the major effect of angiotensin and thromboxane is to potentiate the release of neurotransmitter. In the present study no attempt was made to measure renal angiotensin; however, it was clear that intrarenal infusion of saralasin in doses that blocked the effects of equimolar doses of exogenous All significantly attenuated the RBF decline to RNS in ARF rats indicating that All was at least partially responsible for the adrenergic vascular hypersensitivity. A similar partial reduction in RBF response to RNS in ARF rats was found with a dose of SQ29548 that inhibited the TXA2 mimetic U44069. The combined inhibition of All and TXA2 with simultaneous saralasin and SQ29548 infusion, which had an additive effect, obliterated the adrenergic nerve hypersensitivity of the renal vasculature.
While the study was designed so that there was no effect of inhibitors on basal renal hemodynamics, it is of interest that the doses chosen attenuated the responses to RNS and RPP reduction in ARF kidneys without altering basal RBF or RVR in either study group. It is unlikely that the attenuation of hypersensitivity to RNS by saralasin and SQ29548 was due to a vasodilator or other nonspecific vascular effect. In a previous study it was shown that prostacyclin-induced vasodilation was normal in 1 wk NE-ARF kidneys; however, it did not reduce the RBF slope to RNS or RPP reduction (29) . Moreover, a combination of All receptor antagonist and the thromboxane synthetase inhibitor, OKY 046, also has been reported to eliminate hypersensitivity to RNS in NE-ARF (30) .
The results of renal venous norepinephrine measurements were compatible with a potential role for angiotensin and thromboxane in augmenting catecholamine release in response to RNS. While venous norepinephrine efflux measurements were less desirable than actual kidney catecholamine secretion rates, the latter were difficult to obtain because the required volume sample increased plasma norepinephrine concentration. Thus, norepinephrine efflux was considered to be a valid compromise in assessing renal catecholamine activity, because it was determined that neither ARF at 1 wk or RNS increased arterial norepinephrine concentration. The greater increase in norepinephrine efflux with RNS was in all likelihood due to an enhanced release from intrarenal nerve Renal Perfusion Pressure (mm Hg) Figure 7 . Renal blood flow response to renal perfusion pressure reduction before (----) and after (-A-) renal denervation in NE-ARF kidneys. Moss (31) indicated that RPP reduction to 80 mmHg in the normal rat stimulates afferent nerve activity by an R2 chemoreceptor mechanism. The increased afferent nerve impulses related to RPP reduction, in turn, have been shown to increase efferent renal nerve activity (32) . It is reasonable to assume that in the present study de- creasing RPP directly or by reflex mechanisms increases or, at least, does not decrease renal efferent nerve activity. Reduction in RPP by aortic constriction in the present study likely increased arterial pressure above the constriction independently modifying efferent renal nerve impulses by a reflex mechanism (33) . Changes approaching 100% in efferent impulse rate under normal physiologic conditions have a negligible effect on RBF (34) . Thus, while the presumed net increase in efferent nerve activity with RPP reduction was not quantiAdrenergic Nerve Sensitivity in Acute Renal Failure 1537 10 l0r --4--fied, the data indicate that AII and TXA2 activity were required to amplify the neuroeffector response in the kidney. Moreover, even at the same impulse frequency generated by RNS, the vasoconstriction in NE-ARF kidneys was greater than that in control kidneys.
The abnormal autoregulation response in NE-ARF not related to renal nerve activity was not specifically examined in the present experiments. However, some of the data from this and other studies in established postischemic ARF at least indirectly address this problem. The common characteristic of the residual component of abnormal autoregulation in the saralasin + SQ29548 infused and denervated kidneys was the absence of decrease in RVR with reduction of RPP in the autoregulatory range. Thus, free of major adrenergic nerve influence, the resistance arterial vessels in the kidney had reduced physiologic sensitivity. Whereas this observation might suggest that the initial hemodynamic event that induced ARF 1 wk previously also caused sustained ischemic injury of vascular smooth muscle (5), the responsiveness to renal nerve stimulation would argue against this. Therefore, it is more likely that the lack of change in RVR in the absence of exaggerated renal nerve activity represents failure of the control mechanism that mediates vasodilatation to RPP reduction. Because the precise mechanism of vasorelaxation to reduced vessel lumen pressure remains undetermined, it is not possible to identify the defect in this mechanism that occurs in NE-ARF. Recent studies have shown that endothelium-derived relaxing factor (EDRF) activity is depressed after ischemia (29, 35, 36) . This observation suggests the possibility that EDRF may play a role in mediating pressure reduction related vasorelaxation and, in its absence, appropriate vasodilatation may not occur. There is also indirect evidence that ischemic injury to the kidney results in calcium leak into smooth muscle cells (29) . Thus, an alternative potential mechanism for impaired vasorelaxation to pressure reduction is the inability of messengers (such as EDRF) to attenuate entry of calcium into vascular smooth muscle cells.
It is interesting to note that in previous studies where abnormal autoregulation was observed 1-7 d after renal artery clamping of 90 and 40 min in dog (4) and rat (5) , respectively, a paradoxical vasoconstriction to RPP reduction was not observed. Rather, there was an absence, or near absence, of change in RVR as was seen in the present study with renal denervation or saralasin + SQ29548 infusion. While a possible explanation for the different response pattern to RPP reduction is renal nerve injury from the renal artery clamp, recent data from our laboratory suggest that the differences in RBF responses to RPP reduction in the NE-induced and renal artery clamp models may be more complex. It was determined that RBF during NE-induced ischemia was between 0.8 and 1.0 ml/min, whereas, in a 75-min renal artery clamp model in uninephrectomized rats that had the same level of renal dysfunction at 1 wk it was only 50-60 !l/h (37). Thus, the renal artery clamp is a more complete initial ischemia model and may cause injury to vascular smooth muscle as suggested by the morphology studies of Matthys et al. (5) . It is possible that vascular smooth muscle cell necrosis is sufficiently severe that the renal vasculature would be unresponsive to any vasoactive stimulation and thus would show a different pattern of RBF response to RNS than was seen with the incomplete ischemia model used in the present study.
